Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells

Gefitinib (Gef) provides clinical benefits to non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. However, acquired resistance (AR) is a major obstacle to effective Gef therapy. This study demonstrated that resveratrol (Res) could synergize with Gef to inhibit the proliferati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yinsong, He, Wenjuan, Gao, Xiujuan, Li, Bin, Mei, Chenghan, Xu, Rong, Chen, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669414/
https://www.ncbi.nlm.nih.gov/pubmed/26635117
http://dx.doi.org/10.1038/srep17730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669414/
https://www.ncbi.nlm.nih.gov/pubmed/26635117
http://dx.doi.org/10.1038/srep17730

Ejemplares similares